Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients’ data

The gold standard endpoint to evaluate the effect of treatment for hepatocellular carcinoma (HCC) is overall survival (OS), but it requires a longer follow-up period to observe. This study aimed to identify whether disease-free survival (DFS) could be used as a surrogate endpoint for OS to assess th...

Descripción completa

Detalles Bibliográficos
Autores principales: Huan, Hong-Bo, Wu, Li-Li, Lau, Wan-Yee, Wen, Xu-Dong, Zhang, Liang, Yang, Da-Peng, Wang, Xi-Shu, Bie, Ping, Xia, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685749/
https://www.ncbi.nlm.nih.gov/pubmed/29163828
http://dx.doi.org/10.18632/oncotarget.18853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685749/
https://www.ncbi.nlm.nih.gov/pubmed/29163828
http://dx.doi.org/10.18632/oncotarget.18853

Ejemplares similares